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Abstract
Aims—β-blockers (BB) are strongly recommended after an acute coronary syndrome (ACS),
although all patients may not benefit. Causes for variable patient responses to BB are unknown.
Given that myocardial ischemia and BB influence metabolic processes regulated by peroxisome
proliferator-activated receptor α (PPARα), we hypothesized that interactions between
polymorphisms of the PPARα gene (PPARA) and BB treatment would influence clinical outcome
following ACS.
Patients & methods—Patients were prospectively enrolled into an ACS registry. A total of 735
ACS patients were genotyped. Mortality and cardiac rehospitalization through 1 year were analyzed
in relation to PPARA genotype and BB prescription (597 BB; 138 no BB) at discharge.
Results—Significantly different outcomes associated with BB therapy were observed according to
PPARA IVS7 2498 genotype (p = 0.002 for interaction). PPARA IVS7 2498 GG homozygous patients
discharged on BB had decreased cardiac rehospitalization (hazard ratio [HR]: 0.52; 95% CI: 0.32–
0.86; p = 0.011), while C allele carriers discharged on BB had nearly threefold increased cardiac
rehospitalization (HR: 2.92; 95% CI: 1.32–6.92; p = 0.015; genotype interaction p = 0.0005)
compared with patients not on BB. PPARA genotype was also associated with differences in
PPARα expression, with significantly increased mRNA levels in myocardial samples from normal
hearts among GC heterozygotes compared with GG homozygotes (p = 0.04). Transgenic mice with
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cardiac-specific overexpression of PPARα showed significantly reduced myocardial contractile and
chronotropic responses to the β-sympathomimetic dobutamine (p < 0.05) compared with wild-type
littermates, supporting the hypothesis that increased PPARα levels result in a blunted β-adrenergic
response.
Conclusions—PPARA IVS7 2498 genotype is associated with heterogeneity in 1-year outcome
in response to BB among patients following ACS, and may predict which patients benefit from BB
therapy, putatively related to the effect of myocardial PPARα expression on β-adrenergic
responsiveness.
Keywords
acute coronary syndrome; β-adrenergic receptors; β-blockers; myocardial ischemia; peroxisome
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More than 1.6 million patients are hospitalized with an acute coronary syndrome (ACS) in the
USA each year [101]. In accordance with practice guidelines and quality performance measures
[1-3], the majority of these patients are discharged on β-blocker (BB) therapy. This practice
stems from randomized clinical trials that have demonstrated, on average, an overall benefit
of BB therapy for ACS patients [4,5]. However, recent studies suggest that some patients do
not benefit from treatment with BB and others may even be harmed [6,7]. While the basis for
the observed heterogeneity in response to BB is unknown, one largely unexplored factor is an
individual patient’s genetic profile. Recently, we reported that genetic variation in the
adrenergic β-2 receptor gene (ADRB2) is strongly associated with mortality after BB therapy
among ACS patients [8].
Peroxisome proliferator-activated receptor α (PPARα) is a lipid-activated nuclear receptor
transcription factor that controls expression of genes involved in myocardial energy
metabolism. Animal studies have shown that PPARα regulates myocardial metabolism under
basal conditions and in response to physiologic stressors, including myocardial ischemia
[9-15]. BBs can also affect myocardial energy metabolism by decreasing systemic lipolysis
and myocardial fatty acid oxidation [16,17], suggesting that the therapeutic response to BBs
may be mediated, in part, by cellular lipid metabolic pathways.
The influence of PPARA genotype on clinical outcomes among patients with ACS and
specifically in response to BB therapy, has not been reported. We therefore sought to investigate
the relationship of PPARA genotype with response to BB therapy following hospitalization for
ACS. We examined a SNP in PPARA (PPARA IVS7 2498 G>C) that has previously been
reported to be associated with cardiac phenotypes. Specifically, the PPARA IVS7 2498 SNP
has been associated with degree of physiologic (in response to intense exercise training) and
pathologic (hypertensive) cardiac hypertrophy, progression of coronary artery disease and
response to lipid-lowering medications (fibrates) [18-21]. Given that it has been postulated that
the associations identified with the PPARA IVS7 2498 G>C SNP could be related to its being
in incomplete linkage dis-equilibrium (LD) with PPARA Leu162Val and PPARA IVS1 11394
A>C SNPs [19,22], we also investigated, as a secondary analysis, the individual relationship
of these PPARA SNPs and the relationship of PPARA haplotype with response to BB therapy
following hospitalization for ACS.
Patients & methods
Subjects
Patients were prospectively enrolled into an ACS registry at two Kansas City, KS, USA,
hospitals as previously described [8,23]. Between 1st March 2001 and 31st October 2002, 1199
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patients met the criteria for ACS using standard, accepted definitions of myocardial infarction
(MI; n = 680) and unstable angina (UA; n = 519) [24,25]. ST-elevation MI (STEMI) patients
presented with suggestive cardiac symptoms, diagnostic electrocardiogram (EKG) changes
(ST segment elevation or new-onset left bundle branch block [LBBB]), and a positive troponin
blood test. Non-STEMI (NSTEMI) patients presented with suggestive cardiac symptoms and/
or EKG changes (e.g., ST segment depressions and/or T wave changes), and a positive troponin
blood test. UA patients presented with suggestive cardiac symptoms, as defined by at least one
of the following: new onset angina (<2 months) of at least Canadian Cardiovascular Society
Classification class III, prolonged (>20 min) rest angina, recent (<2 months) worsening of
angina, or angina that occurred within 2 weeks of a previous MI [25]. Although EKG changes
were not a requirement for diagnosis, nearly half of UA patients had ischemic EKG changes
on admission (LBBB 4%, ST-elevations 9%, ST-depressions 12%, T-wave inversions 22%).
By definition, all UA patients had a negative troponin blood test. To further increase the
specificity of the UA diagnosis, those patients with a diagnostic study that excluded obstructive
coronary disease, cardiac perfusion defects or segmental wall motion abnormalities (e.g.,
coronary angiography, nuclear or echocardiographic stress testing; n = 125) or confirmed an
alternative explanation for their presentation (e.g., esophagogastroduodenoscopy) were
excluded. Three physicians reviewed the charts of all patients with diagnostic uncertainty (n
= 45) and attained consensus on the final diagnosis. Thrombolysis in Myocardial Infarction
(TIMI) UA/NSTEMI score was defined using standard, accepted definitions [26].
Each patient was prospectively interviewed during hospitalization to ascertain sociodemo-
graphic, economic and health status characteristics. Detailed chart abstractions were performed
to obtain patients’ medical history, laboratory results, disease severity and the processes of
inpatient care. The study was approved by the Institutional Review Boards of both institutions
and written informed consent was provided by each participant with separate consent for the
genetic analysis. Race was self-reported. Although there were no differences in gender (93.2%
of men vs 92.1% of women), Caucasians (91.5% vs 98.3%; p < 0.001) and older patients (mean
age for those consenting = 61 ± 13 years vs 65 ± 13 years for those not consenting; p = 0.004)
were less likely to consent to DNA testing. A total of 735 patients enrolled in the genetic
substudy had discharge medication status known, constituting the cohort for the current
analysis.
Outcomes assessment
All-cause mortality and repeat hospitalization was captured by query of the Social Security
Death Masterfile on 1st March 2006, by examination of hospital records and/or telephone
follow-up. Hospitalizations for chest pain, heart failure, myocardial infarction or coronary
revascularization were defined as cardiac.
Genotyping
Genetic analyses were approved by the Institutional Review Board of Washington University,
WA, USA. Specimens were processed in compliance with Health Insurance Portability and
Accountability Act (HIPPA) guidelines. DNA isolation, extraction and amplification were
performed as previously described [27]. Pyrosequencing was performed using the PSQ™ HS
96A system (Biotage, MA, USA) with MA v2.0 software as previously described [27] using
PCR primers (1 pM), 1 ng DNA and conditions listed in Table 1.
Human cardiac tissue studies
Cardiac tissue samples were obtained from 34 hearts with no history of myocardial dysfunction
and with normal left ventricular ejection fraction determined by echocardiography donated for
orthotopic cardiac transplantation but declined for reasons related to size or ABO blood type
mismatch. Consent for donation of cardiac tissue for research purposes was obtained from
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family members by the organ donor organization covering the Colorado—Wyoming—
Montana region (Donor Alliance). A total of 0.5 μg of total RNA isolated from human cardiac
tissue using an RNeasy® kit (Qiagen Inc., CA, USA) with the addition of DNase was reverse
transcribed into cDNA using the SuperScript III™ first strand cDNA synthesis kit (Invitrogen,
CA, USA) and random primers. (Typically, 0.1 ng of cDNA, 12.5 nM of each primers and
Power Syber Green PCR Master Mix [ABI] with ROX as an internal control were used in the
RT-PCR reactions). Data were normalized to 18S expression. eactions were performed in
triplicate using the ABI7300 system. The following human-specific primer probe sets were
used to detect specific gene expression: hPPARα: Forward: 5′-
CGGAGTCCACGCGTGTGAA-3′; hPPARα: Reverse: 5′-
GCTGCGGTCGCACTTGTCAT-3′.
Animal studies
All animal experiments and euthanasia protocols were performed in compliance with the
National Institutes of Health guidelines for humane treatment of animals and approved by the
Animal Care Committee of Washington University. Transgenic mice with the PPARα gene
downstream of the myosin heavy chain promoter, resulting in cardiac-specific overexpression
of PPARα (MHC-PPARα) have previously been described [28].
In vivo cardiac hemodynamic studies were performed as previously described [29] in intubated,
ventilated adult (10–12 weeks) MHC-PPARα mice (n = 5) and age-matched wild-type control
littermates (n = 4) anesthetized with thiopental sodium (60 mg/kg). Hemodynamic
measurements were recorded, using a 1.4-Fr high-fidelity micromanometer catheter (Millar
Instruments, TX, USA) inserted into the left ventricle retrograde across the aortic valve, at
baseline and 3 min following the start of each incremental dose of continuously infused
intravenous dobutamine (2, 4, 8, 16 and 32 ng/g body weight/min, respectively). Pressure data
(continuous aortic pressure, left ventricular systolic and diastolic pressure, heart rate and the
derivative of left ventricular pressure over time [dP/dt]) was acquired and digitized with the
BioBench computer software data acquisition system (National Instruments).
Statistical analyses
Hardy—Weinberg equilibrium was assessed by χ2 in Caucasians and African—Americans
separately. Pair wise linkage (D’) and haplotype analysis was carried out using the
Polymorphism and Haplotype Analysis Suite [30]. Patient characteristics were summarized
after stratification by discharge BB status and genotype. Continuous variables were reported
as mean plus or minus standard deviation and compared using t-tests. Lipid values had skewed
distributions, were log-transformed prior to analysis, and were summarized by median and
interquartile range. Categorical variables were summarized by frequency and compared using
χ2 or Fisher’s exact tests, when the expected cell size was less than 5.
The primary outcome was time to rehospitalization for cardiac events through 12 months. Time
to all-cause mortality, to the combined end point of all-cause mortality or cardiac
rehospitalization, and to all-cause rehospitalization were also examined. Event rates by
PPARA IVS7 2498 genotype and by BB status within PPARA IVS7 2498 genotypes were
calculated using Kaplan—Meier analysis and compared using log-rank tests. (GC and CC
genotypes were combined into one group due to the low minor allele frequency of C allele).
The relative hazard associated with BB use within genotype was estimated using Cox
proportional hazard models, including BB, genotype and BB by genotype interaction, both in
crude analysis and adjusting for other patient and process of care characteristics (receipt of
aspirin within 24 h of admission, angiotensinconverting enzyme inhibitor at discharge for
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patients with left ventricular systolic dysfunction, aspirin at discharge, tobacco education for
current smokers, and whether reperfusion was done in a timely fashion) [101].
To account for the nonrandom allocation of BB therapy to patients, propensity scores for BB
use were calculated using nonparsimonious logistic regression models that included all
variables in Table 2 as well as second-order interactions with p-values less than 0.2. The
resulting model had good discrimination (c = 0.74) and sufficient overlap between BB groups
to permit adjustment. Propensity for BB use (on the logit scale) was then included as a covariate
in the proportional hazards model, along with site and Table 3 variables that were significantly
associated with PPARA IVS7 2498 genotype. All continuous variables were modeled using
restricted cubic splines [31]. Proportional hazard assumptions were verified using Schoenfeld
residuals. p-values less than 0.05 were considered statistically significant. Analyses were
performed using SAS version 9.1 (SAS Institute, Inc., NC, USA) and R version 2.2.0 [32]. In
addition to our primary analysis of the association of PPARA IVS7 248 genotype with cardiac
rehospitalization through 12 months, we performed a secondary analysis where PPARA IVS7
2498 SNP and PPARA haplotype were added to the proportional hazards model, individually
and together, to assess which provided the most prognostic information on cardiac outcomes
or on BB response. These analyses were performed among African—Americans and
Caucasians separately, to minimize confounding by racial admixture. Given that three SNPs
contributed to this analysis, a conservative Bonferroni correction was applied and a p-value of
less than 0.016 was considered statistically significant.
Hemodynamic measurements (heart rate and dP/dt) and mRNA expression level values were
summarized by mean and standard deviation and compared using t-tests. p-values less than
0.05 were considered statistically significant.
Results
Baseline characteristics & PPARA genotype frequencies
Of the 735 samples from consecutive ACS patients in the genetic substudy, genotypes for
PPARA IVS7 2498, PPARA IVS1 11394 and PPARA Leu162Val SNPs were successfully
obtained in 698 (95%), 703 (96%) and 696 (95%), respectively. None of the variants deviated
significantly from Hardy—Weinberg equilibrium. PPARA IVS7 2498 C and PPARA IVS1
11394 C alleles exhibited significantly different frequency in Caucasian and African—
American ACS patients (PPARA IVS7 2498: 0.20 vs 0.67; PPARA IVS1 11394: 0.43 vs 0.30,
respectively; p < 0.001). Baseline clinical and demographic data are listed in Tables 2 & 3 for
the patients in whom genetic specimens were acquired. When the patients were stratified
according to PPARA IVS7 2498 genotype (Table 3), univariate analyses demonstrated
significant differences in age, race, chronic heart failure, hyperlipidemia, renal failure,
triglycerides, ACS type, TIMI UA/NSTEMI risk score, receipt of cardiac catheterization and
revascularization. Compared with patients with the PPARA IVS7 2498 GG genotype, carriers
of the PPARA IVS7 2498 C allele (GC or CC genotype) were younger (59.4 ± 12.6 years vs
61.4 ± 12.3 years), had less hyperlipidemia (56.0 vs 63.4%) and had lower fasting serum
triglycerides (140 vs 146 mg/dl). In addition, they had higher prevalence of chronic heart failure
(10.7 vs 5.6%), and renal failure (3.9 vs 1.5%) and were less likely to receive cardiac
catheterization and revascularization. Most of the patients who were discharged on BB were
discharged on metoprolol (∼66%), atenolol (∼8%) or carvedilol (∼6%). There was no
significant difference between BB when PPARA IVS7 2498 GG homozygotes were compared
with PPARA IVS7 2498 C allele carriers (Table 4).
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Interaction between PPARA IVS7 2498 genotype & BB treatment influences clinical outcome
following ACS
In unadjusted analyses, PPARA IVS7 2498 genotype showed no direct association with all-
cause mortality (p = 0.46), all-cause rehospitalization (p = 0.12), cardiac rehospitalization (p
= 0.45), or all-cause mortality and cardiac rehospitalization (p = 0.44; data not shown) through
1 year (Figure 1). However, a significant PPARA IVS7 2498 genotype by BB therapy
interaction effect on cardiac rehospitalization was observed (p = 0.002 for interaction; Figure
2). Compared with patients not discharged on BB, at 1 year, patients with the PPARA IVS7
2498 GG genotype who were discharged on BB showed significantly decreased cardiac
rehospitalization (p = 0.002). By contrast, patients with the GC or CC genotype receiving BB
therapy showed a trend toward increased cardiac rehospitalization (p = 0.058) compared with
patients not receiving BB therapy. A significant genotype by BB interaction was also found
for all-cause rehospitalization (interaction p-value = 0.003) and the combined end point of all-
cause mortality or cardiac rehospitalization (interaction p-value = 0.008) but not for all-cause
mortality alone (interaction p-value = 0.44). When genotypes were compared within treatment
groups, there was significantly increased cardiac rehospitalization in the non-BB-treated
patients with the PPARA IVS7 2498 GG genotype compared with the non-BB treated patients
with the PPARA IVS7 2498 GC or CC genotypes (Figure 2; p < 0.001). There was no significant
difference in cardiac rehospitalization between genotype groups if only the BB-treated group
was examined.
In multivariable analysis adjusting for propensity of BB therapy and all factors that differed
by PPARA IVS7 2498 genotype, genotype remained an independent predictor of response to
BB therapy. Among ACS patients homozygous for the PPARA IVS7 2498 GG genotype,
discharge on BB therapy was associated with a 48% relative risk reduction in cardiac
rehospitalization (hazard ratio [HR]: 0.52; 95% CI: 0.32–0.86; p = 0.011). Discharge on BB
in carriers of the PPARA IVS7 2498 C allele was associated with a nearly threefold relative
increase in the risk of cardiac rehospitalization (HR: 2.92; 95% CI: 1.32–6.92; p = 0.015;
genotype interaction p = 0.0005). Similar results were found for the combined end point of all-
cause mortality plus cardiac rehospitalization, although the reduction in all-cause mortality and
cardiac rehospitalization observed in the GG homozygous group was not statistically
significant (HR: 0.73; 95% CI: 0.44–1.20; p = 0.21 for GG homozygous; HR: 2.73; 95% CI:
1.23–6.06; p = 0.014 for C allele carries; p-value for interaction = 0.005). HRs and CIs are
shown in Figure 3.
Population stratification
Given the racial differences in allele frequency for PPARA IVS7 2498, the effect of PPARA
genotype on response to BB therapy was examined separately in Caucasian subjects, our largest
racial group. The results were consistent with the findings in the entire group, showing a
significant genotype by BB interaction (p = 0.006 for interaction; Figure 4). Additional analyses
demonstrated that there was no difference in cardiac rehospitalization when stratified by race
and there was no significant race by BB therapy interaction (p = 0.66). Collectively, these data
suggest that the observed effects of BB on outcome as a function of PPARA IVS7 2498
genotype are independent of race.
The PPARA IVS7 2498 genotype by BB interaction is not affected by PPARA Leu162Val or
PPARA IVS1 11394 genotype
Since haplotype analysis may contribute additional information on the association of genetic
variation with phenotypes, we assessed if additional PPARA variants provided improved
association with cardiac outcome or affected genotype by BB interaction. SNP and haplotype
association analyses were performed among African—Americans and Caucasians separately.
No statistically significant association was observed between the rare variants of PPARA IVS7
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2498 and PPARA Leu162Val or PPARA IVS1 11394 in the African—American patients (Table
5). Incomplete LD was observed between the rare variants of each of the PPARA SNPs in
Caucasians (Table 5).
A multivariate proportional hazards model predicting outcome was used to assess the
independent contribution of the main effect for PPARA IVS7 2498 SNP and the main effect
of the haplotype, in Caucasian subjects, for this region as well as their interactions with BB
use. The PPARA IVS7 2498 SNP main effect was significant (p = 0.012) and its interaction
with BB use was also significant (p = 0.0156). Neither the main effect for the haplotype nor
its interaction with BB use were significant, suggesting that the haplotype did not provide
significant predictive power for outcome above that provided by PPARA IVS7 2498 alone.
Therefore, once the genotype at PPARA IVS7 2498 was known, haplotype did not provide any
additional prognostic information on cardiac outcomes or differential response to BB versus
non-BB treatment strategies.
PPARA IVS7 2498 GC heterozygote individuals have increased cardiac PPARα mRNA
expression compared with GG homozygote individuals
To investigate the potential mechanism of the clinical association, we determined levels of
PPARα mRNA expression in cardiac tissue from 34 hearts (17 GG and 17 GC; none of the
individuals were CC homozygotes) with no history of myocardial dysfunction and with normal
left ventricular ejection fraction determined by echocardiography donated for orthotopic
cardiac transplantation but declined for reasons related to size or ABO blood type mismatch.
Mean PPARα expression in cardiac tissue from PPARA IVS7 2498 GC heterozygote
individuals was significantly greater than expression in PPARA IVS7 2498 GG homozygote
individuals (Figure 5; 1.20 ± 0.30 vs 0.94 ± 0.40; p = 0.04).
Hemodynamic response to β-adrenergic stimulation is influenced by activation of the cardiac
PPARα pathway
To determine the effect of increased PPARα expression on β-adrenergic responsiveness, we
studied changes in heart rate and contractility in response to incremental doses of the β-
sympathomimetic dobutamine in an animal model that mimics the relative differences in
cardiac PPARα expression demonstrated by our mRNA expression experiments in humans.
Transgenic mice with cardiac-specific overexpression of PPARα (MHC-PPARα) [28],
compared with nontransgene littermates, had significantly blunted response, as determined by
myocardial dP/dt and heart rate, to incremental doses of the β-sympathomimetic dobutamine
(Figure 6).
Discussion
Our results demonstrate a significant association between PPARA IVS7 2498 genotype and 1-
year outcome in response to BB versus non-BB treatment strategies among ACS patients. This
association was observed after multivariable adjustment, including adjustment for the
propensity to be prescribed a BB, and suggests there may be both benefit and potential harm
associated with BB therapy among ACS patients as a function of patients’ PPARA genotype.
While patients with the PPARA IVS7 2498 GG genotype (56% of our population) who were
discharged on BB showed significantly decreased cardiac rehospitalization rates compared
with similar patients not receiving BB therapy (p = 0.002), patients with the GC or CC genotype
receiving BB therapy showed a trend toward increased cardiac rehospitalization rates (p =
0.058). Although this study was not a randomized trial of BB treatment, and the observed
associations cannot prove causality, these data support a potentially important
pharmacogenetic association between patients’ genotype, treatment and outcomes.
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Moreover, we observed marked differences in cardiac rehospitalization rates between genotype
groups in the non-BB treated patients, such that the patients with the PPARA IVS7 2498 GG
genotype demonstrate significantly increased cardiac rehospitalization in the absence of BB
than untreated PPARA IVS7 2498 C allele carriers. Whilst a marked reduction in cardiac
rehospitalization is seen with BB in patients with the PPARA IVS7 2498 GG genotype, it still
does not attain the favorable outcomes of untreated C-carriers, although their cardiac
rehospitalization rates are virtually identical to those of C-carriers treated with BB (Figure 2).
These data suggest that an underlying physiologic difference in the myocardium related to
PPARA genotype may result in patients with the PPARA IVS7 2498 GC/CC genotypes gaining
at best, no benefit, and at worst, harm, from BB therapy. By contrast, patients with the
PPARA IVS7 2498 GG genotype derive a significant benefit from BB treatment post-ACS.
The mechanism whereby genetic variation in PPARA IVS7 2498 confers an underlying
physiologic difference in the myocardium and, consequently, a variable response to BB has
never been reported. We propose, based on our cardiac PPARα mRNA expression data, that
the effect may be related to differential PPARα activity that modulates myocardial responses
to β-adrenergic stimulation via direct or indirect metabolic effects. In our experiments
comparing quantitative responses to β-adrenergic stimulation, we observed blunted adrenergic
response in transgenic mice with cardiac-specific overexpression of PPARα compared with
nontransgene littermates. Taken together, these data suggest that PPARA IVS7 2498 C allele
carriers at baseline are already less responsive to β-adrenergic stimulation compared with GG
homozygotes, reducing or eliminating the mechanism of benefit derived from BB
administration after ACS and potentially unmasking hazardous effects.
Although these data do not follow the classic pharmacogenetic paradigm where the difference
in genotype groups is exaggerated when stratified by treatment, this association represents an
important pharmacogenetic interaction. If validated and confirmed by additional prospective
studies, these data provide evidence that ACS patients may benefit from being genotyped for
the PPARA IVS7 2498 genotype prior to initiating BB therapy. Putatively only those ACS
patients with the PPARA IVS7 2498 GG genotype should receive BB while patients with
PPARA IVS7 2498 GC/CC genotypes should be considered for alternative therapy.
Although the PPARA IVS7 2498 SNP is an intronic SNP with unknown molecular effects, as
discussed above, several strong phenotypic associations of this SNP have been previously
described [19,33-35]. The PPARA IVS7 2498 SNP has been associated with degree of
physiologic and pathologic cardiac hypertrophy, progression of coronary artery disease and
response to lipid-lowering medications [18-21]. It has also been postulated that the associations
identified with the PPARA IVS7 2498 SNP could be related to its being in LD with PPARA
Leu162Val and PPARA IVS1 11394 SNPs. The results of our haplotype and statistical
remodeling analyses, however, do not provide evidence to support this speculation. It is quite
possible, however, that the PPARA IVS7 2498 SNP is in LD with another, as yet undiscovered,
coding or promoter SNP. Alternatively, given its location and its association with different
levels of PPARα mRNA expression, this SNP may disrupt a microRNA site or be in LD with
a SNP that disrupts microRNA site. These possibilities clearly warrant further investigation.
Some potential limitations of this study should be considered when interpreting these results.
First, the blood samples were obtained from a subset of participants in a registry conducted at
two hospitals in a single city. The lack of more diversity in the population and the relatively
modest number of patients may have limited the ability to examine the effect of genotype on
certain outcomes. We did not find a significant association between PPARA IVS7 2498
genotypes and 1-year survival following ACS or a genotype-by-BB therapy interaction for
mortality, although the study had limited power to detect such an association. An additional
concern is the potential introduction of selection bias in either patients who participated in the
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genetic portion of our study or in whom BB therapy was recommended. However, it is unlikely
that either patients refusing to participate or physicians initiating BB therapy were aware of
patients’ genotype. In addition, we did not have access to pharmacy records and were not able
to independently confirm that patients remained on BB for the entire year. However, a previous
investigation suggests that approximately 80% of ACS patients discharged on BB will continue
taking them for the next year [36]. Finally, this was not a randomized clinical trial of BB
stratified by genotype. Although we used propensity models to adjust for observable bias
associated with the nonrandom allocation of BB therapy, residual confounding cannot be
definitely excluded. We propose that small, genotype-directed prospective studies could be
considered to validate and extend these findings.
Conclusion
In conclusion, our data demonstrate a significant association between the PPARA IVS7 2498
genotype and heterogeneity in 1-year outcome in response to BB versus non-BB treatment
strategies among ACS patients. These observations are the first to link specific sequence
variations in PPARA and response to BB therapy with variable outcomes among patients with
cardiovascular disease; the first to demonstrate differential PPARα mRNA expression in
cardiac tissue resulting from PPARA IVS7 2498 genotype, providing a molecular mechanism
for the clinical associations; and have important practical implications for the treatment of ACS
patients. If confirmed by additional prospective studies, these data provide evidence suggesting
that ACS patients may benefit from genotyping for the PPARA IVS7 2498 genotype prior to
initiating BB therapy.
Future perspective
The PPARs represent promising targets for further advances in pharmacogenetic investigation
and intervention. Our current data support that ACS patients may benefit from genotyping for
the PPARA IVS7 2498 genotype prior to initiating BB therapy. Future studies are anticipated
to confirm these findings in other patient populations and, potentially, to identify other
PPARA genotypes that will predict BB responsiveness. Additional investigation into the
mechanism by which PPARA genotype affects BB responsiveness may provide new insights
into PPAR and β-adrenergic receptor biology. Ultimately, knowledge of relevant PPARA
genotypes, as well as a better understanding of the underlying functional mechanism, may help
guide individualized therapy for patients with ACS.
Executive summary
• PPARA IVS7 2498 genotype showed no direct association with all-cause mortality
(p = 0.46), all-cause rehospitalization (p = 0.12), cardiac rehospitalization (p =
0.45), or all-cause mortality and cardiac rehospitalization (p = 0.44).
• A significant PPARA IVS7 2498 genotype by β-blocker (BB) therapy interaction
effect on cardiac rehospitalization was observed (p = 0.002 for interaction).
• Among acute coronary syndrome patients homozygous for the PPARA IVS7 2498
GG genotype, receiving BB therapy was associated with a 48% relative risk
reduction in cardiac rehospitalization (HR: 0.52; 95% CI: 0.32–0.86; p = 0.011).
• In carriers of the PPARA IVS7 2498 C allele, receiving BB therapy was associated
with a nearly threefold relative increase in the risk of cardiac rehospitalization
(HR: 2.92; 95% CI: 1.32–6.92; p = 0.015; genotype interaction p = 0.0005).
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• Carriers of the PPARA IVS7 2498 C allele have increased cardiac PPARα mRNA
expression compared with GG homozygote individuals (1.20 ± 0.30 vs 0.94 ± 0.40;
p = 0.04).
• Transgenic mice with cardiac-specific overexpression of PPARα, compared with
nontransgene littermates, had blunted response, as determined by myocardial dP/
dt and heart rate, to incremental doses of the β-sympathomimetic dobutamine.
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Kaplan-Meier estimates of mortality (left) and cardiac rehospitalization (right) in acute
coronary syndrome genetic substudy stratified by PPARA IVS7 2498 genotype.
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Kaplan-Meier estimates of cardiac rehospitalization in acute coronary syndrome genetic
substudy.
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Adjusted hazard ratios for β-blocker use in acute coronary syndrome genetic substudy, by end
point and PPARA IVS7 2498 genotype.
Cresci et al. Page 15














Kaplan-Meier estimates of cardiac rehospitalization stratified by PPARA IVS7 2498 genotype
for Caucasians only.
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Mean (± standard error) mRNA expression (determined by rtPCR) from normal cardiac tissue
from PPARA IVS7 2498 GG (n = 17) and GC (n = 17) individuals.
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Mean (± standard deviation) heart rate (top) and dP/dt (bottom) response to incremental doses
of dobutamine in the MHC-PPARα mice (n = 5, triangles) and age-matched wild-type control
littermates (n = 4, circles).
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